TrialCancer chemotherapy and pharmacology2011

A phase I, open-label, randomized crossover study to assess the effect of dosing of the MEK 1/2 inhibitor Selumetinib (AZD6244; ARRY-142866) in the presence and absence of food in patients with advanced solid tumors.

Suzanne Leijen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.